Current status of chemotherapy for the treatment of advanced biliary tract cancer

키워드

참고문헌 (72)

1. Randi G, "Epidemiology of biliary tract cancers: an update", Ann Oncol, 20, pp.146~159 (2009)
2. "Vital statistics" (2010)[URL]
3. Siegel R, "Cancer statistics, 2013", CA Cancer J Clin, 63, pp.11~30 (2013)
4. Kyu-Won Jung, "Prediction of Cancer Incidence and Mortality in Korea, 2012", Cancer Research and Treatment, 44(1), pp.15~31 (2012), 대한암학회
5. Khan SA, "Changing international trends in mortality rates for liver, biliary and pancreatic tumours", J Hepatol, 37, pp.806~813 (2002)
6. Hezel AF, "Systemic therapy for biliary tract cancers", Oncologist, 13, pp.415~423 (2008)
7. Miyakawa S, "Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan", J Hepatobiliary Pancreat Surg, 16, pp.1~7 (2009)
8. Sasaki T, "Improvement of prognosis for unresectable biliary tract cancer", World J Gastroenterol, 19, pp.72~77 (2013)
9. Tada M, "Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers", World J Clin Oncol, 2, pp.158~163 (2011)
10. Glimelius B, "Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer", Ann Oncol, 7, pp.593~600 (1996)
11. Takada T, "Prospective randomized trial of 5-f luorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial", Hepatogastroenterology, 45, pp.2020~2026 (1998)
12. Sharma A, "Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study", J Clin Oncol, 28, pp.4581~4586 (2010)
13. Eckel F, "Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials", Br J Cancer, 96, pp.896~902 (2007)
14. Yonemoto N, "A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer", Jpn J Clin Oncol, 37, pp.843~851 (2007)
15. Doval DC, "A phase II study of gemcitabine and cisplatin in chemotherapynaive, unresectable gall bladder cancer", Br J Cancer, 90, pp.1516~1520 (2004)
16. Thongprasert S, "Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma", Ann Oncol, 16, pp.279~281 (2005)
17. Kim ST, "A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer", Cancer, 106, pp.1339~1346 (2006)
18. Valle JW, "Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study: The UK ABC-01 Study", Br J Cancer, 101, pp.621~627 (2009)
19. Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
20. Okusaka T, "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan", Br J Cancer, 103, pp.469~474 (2010)
21. Andre T, "Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study", Ann Oncol, 15, pp.1339~1343 (2004)
22. Harder J, "Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer", Br J Cancer, 95, pp.848~852 (2006)
23. Andre T, "Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study", Br J Cancer, 99, pp.862~867 (2008)
24. Kim HJ, "A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer", Cancer Chemother Pharmacol, 64, pp.371~377 (2009)
25. Jang JS, "Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial", Cancer Chemother Pharmacol, 65, pp.641~647 (2010)
26. Cho JY, "Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced", metastatic biliary tract carcinoma, 2005, pp.104, 2753~2758
27. Knox JJ, "Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial", J Clin Oncol, 23, pp.2332~2338 (2005)
28. Riechelmann RP, "Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer", Cancer, 110, pp.1307~1312 (2007)
29. Koeberle D, "Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research", J Clin Oncol, 26, pp.3702~3708 (2008)
30. Ueno H, "Phase II study of S-1 in patients with advanced biliary tract cancer", Br J Cancer, 91, pp.1769~1774 (2004)
31. Furuse J, "S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study", Cancer Chemother Pharmacol, 62, pp.849~855 (2008)
32. Sasaki T, "S-1 monotherapy in patients with advanced biliary tract cancer", Oncology, 77, pp.71~74 (2009)
33. Sasaki T, "Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer", Cancer Chemother Pharmacol, 65, pp.1101~1107 (2010)
34. Kanai M, "A multi-institution phase II study of gemcitabine", S-1 combination chemotherapy for patients with advanced biliary tract cancer, 2011, pp.67, 1429~1434
35. Sasaki T, "A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer", Cancer Chemother Pharmacol, 71, pp.973~979 (2013)
36. Morizane C, "Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805)", J Clin Oncol, 30(4) (2012)
37. Kim YJ, "A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer", Ann Oncol, 19, pp.99~103 (2008)
38. Kang MJ, "Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma", Acta Oncol, 51, pp.860~866 (2012)
39. Kim TW, "Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer", Ann Oncol, 14, pp.1115~1120 (2003)
40. Hong YS, "Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer", Cancer Chemother Pharmacol, 60, pp.321~328 (2007)
41. Sanz-Altamira PM, "A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma", Ann Oncol, 12, pp.501~504 (2001)
42. Alberts SR, "CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study", Int J Gastrointest Cancer, 32, pp.107~114 (2002)
43. Jones DV Jr, "Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas", J Clin Oncol, 14, pp.2306~2310 (1996)
44. Papakostas P, "Firstline chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract: a multicentre phase II study", Eur J Cancer, 37, pp.1833~1838 (2001)
45. Philip PA, "Phase II study of erlotinib in patients with advanced biliary cancer", J Clin Oncol, 24, pp.3069~3074 (2006)
46. Ramanathan RK, "A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer", Cancer Chemother Pharmacol, 64, pp.777~783 (2009)
47. Bengala C, "Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial", Br J Cancer, 102, pp.68~72 (2010)
48. El-Khoueiry AB, "SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma", Invest New Drugs, 30, pp.1646~1651 (2012)
49. Bekaii-Saab T, "Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers", J Clin Oncol, 29, pp.2357~2363 (2011)
50. Lubner SJ, "Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study", J Clin Oncol, 28, pp.3491~3497 (2010)
51. El-Khoueiry AB, "SWOG 0941: a phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma", J Clin Oncol, 30(15), pp.4113~ (2012)
52. Gruenberger B, "Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study", Lancet Oncol, 11, pp.1142~1148 (2010)
53. Malka D, "Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: final analysis of a randomized phase II trial (BINGO)", J Clin Oncol, 30(15), pp.4032~ (2012)
54. Lee J, "Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 13, pp.181~188 (2012)
55. Zhu AX, "Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-f luorodeoxyglucose PET with clinical outcome: a phase 2 study", Lancet Oncol, 11, pp.48~54 (2010)
56. Walter T, "Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study", Eur J Cancer, 49, pp.329~335 (2013)
57. Lee MA, "Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases", Jpn J Clin Oncol, 34, pp.547~550 (2004)
58. Sasaki T, "Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer", Invest New Drugs, 29, pp.1488~1493 (2011)
59. Paule B, "Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas", Oncology, 72, pp.105~110 (2007)
60. Oh SY, "Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness", Invest New Drugs, 29, pp.1066~1072 (2011)
61. Suzuki E, "A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer", J Clin Oncol, 28(15), pp.4145~ (2010)
62. Sasaki T, "Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine", Invest New Drugs, 30, pp.708~713 (2012)
63. Lim KH, "Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer", Oncology, 83, pp.57~66 (2012)
64. Roth A, "Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study", Onkologie, 34, pp.469~470 (2011)
65. Yi JH, "A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study", Eur J Cancer, 48, pp.196~201 (2012)
66. Katayose Y, "An analysis of a second-line S-1 monotherapy for gemcitabinerefractory biliary tract cancer", Hepatogastroenterology, 59, pp.691~695 (2012)
67. Kobayashi S, "retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer", Jpn J Clin Oncol, 42, pp.800~806 (2012)
68. Sasaki T, "A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer", J Clin Oncol, 31(4), pp.258~ (2013)
69. Tempero MA, "Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines", J Natl Compr Canc Netw, 10, pp.703~713 (2012)
70. Sasaki T, "Comparing the treatment outcomes between unresectable and recurrent cases receiving gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer: pooled analysis of two prospective studies", J Clin Oncol, 30(4), pp.331~ (2012)
71. Hezel AF, "Genetics of biliary tract cancers and emerging targeted therapies", J Clin Oncol, 28, pp.3531~3540 (2010)
72. Sasaki T, "Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy", Cancer Chemother Pharmacol, 67, pp.847~853 (2011)

관련 논문AI추천